RecruitingRecruiting
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT07033026 · NGM Biopharmaceuticals, Inc
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia
About this study
Evaluation of Efficacy, Safety and Tolerability of NGM120 in a Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Participants with Colorectal Cancer who have Cancer Cachexia
Eligibility criteria
Inclusion Criteria:
1. Documented active diagnosis of colorectal cancer.
2. Cachexia defined by Fearon criteria of weight loss.
3. Signed informed consent.
Exclusion Criteria:
1. Current active reversible causes of decreased food intake.
2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
3. Have cachexia caused by other reasons.
Study design
Enrollment target: 136 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2025-06-25
Estimated completion: 2027-12
Last updated: 2026-04-01
Interventions
Drug: NGM120 Q4WDrug: NGM120 Q8WDrug: Placebo given
Primary outcomes
- • Change from baseline in body weight at Week 12 (12 Weeks)
- • Treatment-emergent adverse events (TEAEs) characterized by type, frequency, severity, timing, seriousness, and relationship to study drug (44 Weeks)
Sponsor
NGM Biopharmaceuticals, Inc · industry
Contacts & investigators
ContactNGM Study Director · contact · NGM120CX@ngmbio.com · 650-727-8800
InvestigatorNGM Study Director · study_director, NGM Biopharmaceuticals, Inc
All locations (28)
NGM Clinical Study SiteRecruiting
Los Angeles, California, United States
NGM Clinical Study SiteRecruiting
Los Angeles, California, United States
NGM Clinical Study SiteRecruiting
Santa Rosa, California, United States
NGM Clinical Study SiteRecruiting
Margate, Florida, United States
NGM Clinical Study SiteRecruiting
Baltimore, Maryland, United States
NGM Clinical Study SiteRecruiting
New York, New York, United States
NGM Clinical Study SiteRecruiting
Toledo, Ohio, United States
NGM Clinical Study SiteRecruiting
Youngstown, Ohio, United States
NGM Clinical Study SiteRecruiting
Dallas, Texas, United States
NGM Clinical Study SiteWithdrawn
Kingwood, Texas, United States
NGM Clinical Study SiteRecruiting
Laredo, Texas, United States
NGM Clinical Study SiteRecruiting
Richmond, Virginia, United States
NGM Clinical Study SiteRecruiting
Appleton, Wisconsin, United States
NGM Clinical Study SiteRecruiting
Tbilisi, Georgia
NGM Clinical Study SiteRecruiting
Tbilisi, Georgia
NGM Clinical Study SiteRecruiting
Tbilisi, Georgia
NGM Clinical Study SiteRecruiting
Tbilisi, Georgia
NGM Clinical Study SiteRecruiting
Tbilisi, Georgia
NGM Clinical Study SiteRecruiting
Goyang, South Korea
NGM Clinical Study SiteRecruiting
Goyang, South Korea
NGM Clinical Study SiteRecruiting
Incheon, South Korea
NGM Clinical Study SiteRecruiting
Seoul, South Korea
NGM Clinical Study SiteRecruiting
Seoul, South Korea
NGM Clinical Study SiteRecruiting
Seoul, South Korea
NGM Clinical Study SiteRecruiting
Suwon, South Korea
NGM Clinical Study SiteRecruiting
Taichung, Taiwan
NGM Clinical Study SiteRecruiting
Taipei, Taiwan
NGM Clinical Study SiteRecruiting
Taoyuan, Taiwan